TSMHT
CRSP icon

Thurston Springer Miller Herd & Titak’s CRISPR Therapeutics CRSP Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.3K Buy
1,637
+1,061
+184% +$55.9K 0.03% 373
2026
Q1 		$27.4K Hold
576
– – 0.01% 689
2025
Q4 		$30.2K Buy
576
+382
+197% +$22.9K 0.01% 621
2025
Q3 		$12.6K Sell
194
-1,271
-87% -$73K 0.02% 329
2025
Q2 		$71.3K Buy
1,465
+120
+9% +$4.64K 0.01% 573
2025
Q1 		$45.8K Buy
1,345
+103
+8% +$4.37K 0.01% 655
2024
Q4 		$48.9K Sell
1,242
-84
-6% -$3.97K 0.01% 544
2024
Q3 		$62.3K Sell
1,326
-20
-1% -$1.01K 0.02% 507
2024
Q2 		$72.7K Buy
+1,346
New +$77.9K 0.02% 473

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's CRSP Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak increased its CRISPR Therapeutics (CRSP) stake by 184% in Q2 2026, buying an estimated $55.9K and bringing the position to 1,637 shares worth $89.3K. The position accounts for 0.03% of the portfolio, ranked #373.

Thurston Springer Miller Herd & Titak first reported a position in CRSP in Q2 2024 and has held it in 9 quarters since. 252 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Thurston Springer Miller Herd & Titak held 1,637 shares of CRISPR Therapeutics worth $89.3K as of Q2 2026.
  • Thurston Springer Miller Herd & Titak bought 1,061 CRISPR Therapeutics shares in Q2 2026, an estimated $55.9K.
  • CRISPR Therapeutics made up 0.03% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #373 holding.
  • Thurston Springer Miller Herd & Titak first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 252 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.